[go: up one dir, main page]

EA201890796A1 - Новое антитело к мезотелину и содержащая его композиция - Google Patents

Новое антитело к мезотелину и содержащая его композиция

Info

Publication number
EA201890796A1
EA201890796A1 EA201890796A EA201890796A EA201890796A1 EA 201890796 A1 EA201890796 A1 EA 201890796A1 EA 201890796 A EA201890796 A EA 201890796A EA 201890796 A EA201890796 A EA 201890796A EA 201890796 A1 EA201890796 A1 EA 201890796A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
mezothelin
contents
mesothelin
nucleic acid
Prior art date
Application number
EA201890796A
Other languages
English (en)
Other versions
EA038654B1 (ru
Inventor
Тон-Сик Ким
Ын Чон Сон
Миджун Ли
Ын-Хи Ли
Миюн О
Чэ Чан Пак
Кису Ким
Сучон Ким
Хён-Квон Лим
Кюхён Ли
Чонхва Вон
Суню Цой
Юн Соуб Пак
Original Assignee
Могам Инститьют Фор Байомедикал Рисерч
Грин Кросс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Могам Инститьют Фор Байомедикал Рисерч, Грин Кросс Корпорейшн filed Critical Могам Инститьют Фор Байомедикал Рисерч
Publication of EA201890796A1 publication Critical patent/EA201890796A1/ru
Publication of EA038654B1 publication Critical patent/EA038654B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение имеет отношение к антителу, специфически связывающемуся с мезотелином (MSLN), нуклеиновой кислоте, кодирующей данное антитело, вектору и клетке-хозяину, содержащей данную нуклеиновую кислоту, способу получения антитела и фармацевтической композиции для лечения рака или опухоли, включающей антитело в качестве активного ингредиента. Антитело, специфически связывающееся с мезотелином, согласно настоящему изобретению обладает высокой аффинностью и специфичностью к антигену, в результате этого стало возможным создание антитела, пригодного для эффективного использования при лечении или диагностике раковых или опухолевых заболеваний.
EA201890796A 2015-09-24 2016-09-23 Новое антитело к мезотелину и содержащая его композиция EA038654B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150135755A KR101782487B1 (ko) 2015-09-24 2015-09-24 신규 항-메소텔린 항체 및 이를 포함하는 조성물
PCT/KR2016/010604 WO2017052241A1 (en) 2015-09-24 2016-09-23 Novel anti-mesothelin antibody and composition comprising the same

Publications (2)

Publication Number Publication Date
EA201890796A1 true EA201890796A1 (ru) 2018-10-31
EA038654B1 EA038654B1 (ru) 2021-09-29

Family

ID=58386441

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890796A EA038654B1 (ru) 2015-09-24 2016-09-23 Новое антитело к мезотелину и содержащая его композиция

Country Status (13)

Country Link
US (1) US10851175B2 (ru)
EP (1) EP3353213B1 (ru)
JP (1) JP6738893B2 (ru)
KR (1) KR101782487B1 (ru)
CN (3) CN108350084B (ru)
AU (1) AU2016328204B2 (ru)
BR (1) BR112018005837A2 (ru)
CA (1) CA2999237C (ru)
EA (1) EA038654B1 (ru)
ES (1) ES2857500T3 (ru)
IL (1) IL258215B (ru)
MX (1) MX2018003470A (ru)
WO (1) WO2017052241A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017283181B2 (en) 2016-06-20 2024-08-15 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
AU2017281157B2 (en) 2016-06-20 2024-07-25 F-Star Therapeutics Limited LAG -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2019005208A1 (en) * 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
KR101966362B1 (ko) * 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
US11548948B2 (en) 2017-12-19 2023-01-10 F-Star Therapeutics Limited FC binding fragments comprising a PD-L1 antigen-binding site
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
JP7397055B2 (ja) 2018-07-12 2023-12-12 エフ－スター セラピューティクス リミテッド Ｃｄ１３７及びｏｘ４０に結合する抗体分子
KR102070016B1 (ko) * 2019-01-21 2020-01-29 (주)녹십자셀 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포
EA202192654A1 (ru) * 2019-03-29 2021-12-30 Грин Кросс Корпорейшн Слитый белок, содержащий анти-мезотелин антитело, анти-cd3 антитело или анти-egfr антитело, биспецифическое или триспецифическое антитело, содержащие его, и их применения
KR102216225B1 (ko) * 2019-06-27 2021-02-17 (주)녹십자셀 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포
WO2022030730A1 (ko) * 2020-08-04 2022-02-10 주식회사 셀렌진 메소텔린에 특이적으로 결합하는 항-메소텔린 키메릭 항원 수용체
EP4194467A4 (en) 2020-08-04 2024-09-04 Cellengene Inc Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin
EP4242235A4 (en) 2021-05-26 2024-03-20 Cellengene Inc CHIMERIC ANTIGEN RECEPTOR WITH ANTI-MESOTHELIN SCFV AND USE THEREOF
KR20230005001A (ko) * 2021-06-30 2023-01-09 (주)이노베이션바이오 메소텔린 특이적 항체 및 이의 용도
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
CN114423789B (zh) * 2021-12-24 2022-09-30 浙江时迈药业有限公司 针对间皮素的抗体及其用途
KR20240043161A (ko) * 2022-09-23 2024-04-03 국민대학교산학협력단 Grp94에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 및 약물을 포함하는 항체 약물 컨쥬게이트
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2429340T3 (es) * 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
MX2010003581A (es) * 2007-10-01 2010-08-02 Bristol Myers Squibb Co Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos.
WO2009054957A2 (en) 2007-10-22 2009-04-30 Cfs Research Llc Methods for diagnosis and treatment of chronic fatigue syndrome
CA2706529C (en) * 2007-11-26 2016-10-25 Bayer Schering Pharma Aktiengesellschaft Anti-mesothelin antibodies and uses therefor
US8357783B2 (en) * 2008-03-27 2013-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human anti-mesothelin monoclonal antibodies
BR112013014527A2 (pt) 2010-12-20 2017-03-07 Genentech Inc anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CA2882753C (en) * 2012-08-21 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
KR20150029457A (ko) * 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도

Also Published As

Publication number Publication date
ES2857500T3 (es) 2021-09-29
US20180346588A1 (en) 2018-12-06
KR20170036503A (ko) 2017-04-03
BR112018005837A2 (pt) 2018-10-09
JP2018532401A (ja) 2018-11-08
CN113603785A (zh) 2021-11-05
JP6738893B2 (ja) 2020-08-12
WO2017052241A1 (en) 2017-03-30
IL258215B (en) 2022-07-01
MX2018003470A (es) 2019-10-30
CN118085094A (zh) 2024-05-28
AU2016328204B2 (en) 2019-03-21
EA038654B1 (ru) 2021-09-29
US10851175B2 (en) 2020-12-01
KR101782487B1 (ko) 2017-09-27
IL258215A (en) 2018-05-31
EP3353213A4 (en) 2019-05-29
CA2999237A1 (en) 2017-03-30
EP3353213A1 (en) 2018-08-01
AU2016328204A1 (en) 2018-04-19
CN108350084B (zh) 2021-09-10
CN113603785B (zh) 2024-01-05
CA2999237C (en) 2021-07-06
CN108350084A (zh) 2018-07-31
EP3353213B1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
MX2021011697A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
EA202092735A1 (ru) Антагонизирующее cd73 антитело
EA201891366A1 (ru) Гуманизированные антитела против cd73
EA201892774A1 (ru) Антитела
EA201492101A1 (ru) Антитела против fcrn
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
PH12019500571A1 (en) Anti-pd-1 antibodies
EA201690503A1 (ru) Антитела
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
PH12018501070A1 (en) Anti-pcsk9 antibody and use thereof
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
BR112017025036A2 (pt) peptídeo; ácido nucleico; parcela de ligação; composição farmacêutica; peptídeos e/ou ácidos nucleicos e/ou parcelas de ligação; peptídeos e/ou ácidos nucleicos e/ou parcelas de ligação para uso; e ácido nucleico para uso
EA201990927A1 (ru) Антитела против lag-3 и способы их применения
AR109825A1 (es) ANTICUERPOS DE INTERFERÓN b Y USOS DE LOS MISMOS